Short Interest in Jupiter Neurosciences, Inc. (NASDAQ:JUNS) Declines By 74.5%

Jupiter Neurosciences, Inc. (NASDAQ:JUNS) saw a large decrease in short interest during the month of July. As of July 15th, there was short interest totaling 239,118 shares, a decrease of 74.5% from the June 30th total of 938,810 shares. Approximately 1.1% of the company’s stock are sold short. Based on an average daily trading volume, of 1,138,425 shares, the days-to-cover ratio is presently 0.2 days.

Institutional Investors Weigh In On Jupiter Neurosciences

Large investors have recently added to or reduced their stakes in the business. Allen Capital Group LLC acquired a new stake in Jupiter Neurosciences during the 4th quarter valued at $31,000. Yorkville Advisors Global LP acquired a new position in shares of Jupiter Neurosciences in the fourth quarter valued at $135,000. Geode Capital Management LLC increased its holdings in shares of Jupiter Neurosciences by 27.8% in the fourth quarter. Geode Capital Management LLC now owns 132,641 shares of the company’s stock valued at $135,000 after purchasing an additional 28,826 shares during the last quarter. Finally, Vestor Capital LLC raised its position in shares of Jupiter Neurosciences by 144,607.2% in the first quarter. Vestor Capital LLC now owns 970,985 shares of the company’s stock valued at $365,000 after purchasing an additional 970,314 shares during the period.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Jupiter Neurosciences in a research report on Wednesday, June 24th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company currently has an average rating of “Sell”.

Jupiter Neurosciences Price Performance

NASDAQ JUNS traded down $0.03 during trading on Friday, reaching $0.12. 6,810,308 shares of the company’s stock were exchanged, compared to its average volume of 21,126,814. The business has a 50 day moving average price of $0.22 and a 200-day moving average price of $0.43. The stock has a market capitalization of $4.39 million, a P/E ratio of -0.45 and a beta of 1.73. Jupiter Neurosciences has a fifty-two week low of $0.11 and a fifty-two week high of $1.84.

Jupiter Neurosciences (NASDAQ:JUNS) last released its quarterly earnings data on Thursday, May 14th. The company reported ($0.06) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.05) by ($0.01). The business had revenue of $0.02 million during the quarter, compared to analysts’ expectations of $0.23 million.

Jupiter Neurosciences Company Profile

Jupiter Neurosciences, Inc, a clinical stage research and development pharmaceutical company, develops resveratrol platform product primarily for the treatment of neuro-inflammation. It is developing JNS101 that is in Phase II trials for the treatment of Friedreich's Ataxia, a rare disease that causes damage to the nervous system, as well as mobility dysfunctions; and JNS102, which is in Phase II trials for the treatment of mucopolysaccharidosis Type I. The company is also developing JNS107 that is in Phase II trials for the treatment of MELAS Syndrome; and JNS108, which is in Phase II trials for the treatment of mild cognitive impairment/early Alzheimer's disease.